Quintiles will continue to grow through acquisitions, says S&P

By Dan Stanton contact

- Last updated on GMT

S&P has upgraded Quintiles to BB+ rating
S&P has upgraded Quintiles to BB+ rating

Related tags: Stock market, Initial public offering

Quintiles has been upgraded to stable by ratings agency Standard & Poor after a second stock offering and the consolidation of debt through a $300m securitisation facility.

Since Quintiles went public again in 2013, the firm has bought medical device and diagnostics CRO Novella Clinical​ and analytics and tech consultancy firm Encore Health Resources​ but in rating the world’s largest clinical research organisation (CRO) ‘stable’, Standard & Poor (S&P) believes more acquisitions are to come.

“Our stable outlook on Quintiles reflects our expectation that the company will maintain leverage around 3x over time,”​ the agency said in a note. “This incorporates our belief that the company will continue to grow through acquisitions, as well as our expectation that leverage may temporarily increase or decrease from this level because of the timing and magnitude of acquisitions.”

The agency continued to add it believes “the CRO industry continues to consolidate and Quintiles could be involved in large-scale acquisition activity to the extent that the right strategic target was available.”

$300m securitisation facility

S&P’s upgrade from BBB to BB+ was further encouraged by recent financial movements within Quintiles, including the offering up of 13 million shares in a secondary public offering last month, resulting in around half of Quintiles' shares now being owned by outside shareholders, ie those who are not board members of execuitve managment.

This, according to S&P credit analyst Shannan Murphy, has led to “increasing confidence in the company's financial policies.”

This is backed further by a securitisation facility deal announced in an SEC filing Monday​ which frees up some of Quintile’s $2bn long-term debt (according to Q3 2014 results​).

The securitisation, which consists of a $275m term loan and a $25m revolver issued by PNC Bank, has been assigned 'BBB' rating and '1' recovery rating by S&P, indicating expectation for very high recovery in the event of default.

Related news

Show more

Related products

show more

What are the building blocks of DCTs?

What are the building blocks of DCTs?

Medable | 26-Apr-2021 | Technical / White Paper

How to create a seamless experience across eConsent, eCOA and more.

Over the past year, tremendous progress was made toward digitizing and...

How a clinical metadata repository helps with data

How a clinical metadata repository helps with data

Formedix | 22-Mar-2021 | Technical / White Paper

This article covers the various ways a clinical metadata repository helps with data quality, and in turn, with data quality in the clinical trials process....

Introduction to eLAS®

Introduction to eLAS®

Clinical Ink | 08-Mar-2021 | Product Brochure

Clinical Ink has developed a unique offering — the electronic Lupus Assessment Suite (eLAS®) to address fundamental challenges impacting systemic lupus...

Related suppliers

Follow us

Products

View more

Webinars